Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biodesix ( (BDSX) ) has shared an update.
On September 15, 2025, Biodesix, Inc. implemented a one-for-twenty reverse stock split of its common stock, following approval from its Board of Directors and stockholders earlier in May 2025. This move, effective as of September 15, 2025, aims to adjust the trading price of its common stock, with no fractional shares issued; instead, stockholders will receive cash for fractional entitlements. Additionally, on September 12, 2025, the company filed a Certificate of Elimination to remove provisions related to its Series A Non-Voting Convertible Preferred Stock, marking a strategic shift in its stock structure.
The most recent analyst rating on (BDSX) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Biodesix stock, see the BDSX Stock Forecast page.
Spark’s Take on BDSX Stock
According to Spark, TipRanks’ AI Analyst, BDSX is a Neutral.
Biodesix’s overall stock score is primarily impacted by financial instability due to high leverage and negative profitability. While there are positive signs in revenue growth and improved gross margins, these are overshadowed by ongoing losses and cash flow challenges. The technical analysis suggests some short-term momentum, but the valuation remains unattractive due to negative earnings. The earnings call provides a balanced view of achievements and challenges, but the financial risks remain significant.
To see Spark’s full report on BDSX stock, click here.
More about Biodesix
Biodesix, Inc. is a Delaware-based company operating in the biotechnology industry, focusing on the development of diagnostic solutions.
Average Trading Volume: 2,597,777
Technical Sentiment Signal: Sell
Current Market Cap: $55M
Find detailed analytics on BDSX stock on TipRanks’ Stock Analysis page.